Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.67 |
| ▸ | TP53 | P04637 | 3/20 | 0.67 |
| ▸ | THRB | P10828 | 3/20 | 0.61 |
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.57 |
| ▸ | TRPC3 | Q13507 | 3/20 | 0.55 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.53 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | PNLIP | P16233 | 1/20 | 0.45 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7323958 | 0.85 | MAPT (0.87) | MAPTTP53THRBORAI1TRPC3 | |
| SCHEMBL7326987 | 0.82 | MAPT (0.62) | MAPTTP53THRBORAI1TRPC3 | |
| SCHEMBL7326256 | 0.81 | ORAI1 (0.67) | MAPTTP53THRBORAI1TRPC3 | |
| SCHEMBL7323633 | 0.81 | MAPT (0.71) | MAPTTP53THRBORAI1TRPC3 | |
| SCHEMBL7325007 | 0.81 | CRACR2A (0.61) | MAPTTP53THRBORAI1TRPC3 | |
| SCHEMBL7323347 | 0.80 | TP53 (0.67) | MAPTTP53THRBORAI1TRPC3 | |
| SCHEMBL7321362 | 0.80 | THRB (0.87) | MAPTTP53THRBORAI1TRPC3 | |
| SCHEMBL7327001 | 0.80 | MAPT (0.61) | MAPTTP53THRBORAI1TRPC3 | |
| SCHEMBL7315027 | 0.79 | THRB (0.69) | MAPTTP53THRBORAI1TRPC3 | |
| SCHEMBL7318760 | 0.79 | ORAI1 (0.74) | MAPTTP53THRBORAI1TRPC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010044445-A1 | AZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES | 2001-11-22 | — | — | US | claimed |
| EP-1068187-A1 | PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES (US) | 2001-01-17 | — | — | EP | claimed |
| WO-1999051580-A1 | PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES (US) | 1999-10-14 | — | — | WO | claimed |
| US-20010044445-A1 | AZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES | 2001-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044445-A1 | AZOLE INHIBITORS OF CYTOKINE PRODUCTION | IL5, IL2, IL4 | MAPT 2674/4885TP53 1903/4885THRB 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.